This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba® (19 October 2012)
| Read the full announcement in PDF format |
Novo Nordisk today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has published their assessment report of Tresiba® (insulin degludec). The report forms the basis of the approval of the product announced on 28 September 2012.
Further information:
Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216 5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company Announcement No 65 / 2012
